Plant-Based Omega-3 Alternatives Evaluated in New Comparative Trial

A recent eight-week animal study published in the journal Lipids has provided comparative data on the efficacy of stearidonic acid-rich (SDA) plant oils.¹ The mouse trial evaluated the metabolic effects of dietary Ahiflower (Buglossoides arvensis) oil against Echium (Echium plantagineum) oil and a control group fed soya oil, which contains no SDA. The findings offer insights for finished product manufacturers and nutraceutical industry professionals seeking viable, plant-based alternatives to marine-derived omega-3 fatty acids.

The study assessed how equal daily dietary intakes (4% of total fats) of these specific oils influenced eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels across various tissues—specifically the heart, brain, liver, and adipose tissue—as well as within blood plasma and erythrocytes. SDA is a precursor of EPA. The researchers concluded that, “dietary supplementation with ALA and SDA derived from Echium and Ahiflower oils, at the doses applied in our model, effectively increased EPA proportions in all analyzed tissues.”

EPA and DHA Accumulation Dynamics

The results highlighted distinct patterns in how the mammalian body processes plant-derived alpha-linolenic acid (ALA) and SDA. Notably, Ahiflower, Echium, and soya oils all maintained DHA levels in the heart and brain comparably. According to the study authors, this indicates that tissue DHA enrichment is closely regulated by physiological constraints regarding tissue incorporation, rather than being limited by inefficiencies in metabolic conversion. Both Ahiflower and Echium oils significantly raised red blood cell (RBC) DHA levels, a major component of the Omega-3 Index, compared to the control soya oil, notes Natures Crops International, commenting on the recently published study.² The company supplied a trademarked Ahiflower oil used in the study.

However, differences emerged regarding EPA accrual. Ahiflower oil raised overall tissue and blood EPA levels in a more pronounced manner than Echium oil, with both outperforming soya oil. Specifically, Ahiflower oil led to significantly higher EPA levels in the RBCs, plasma, and brain than both the Echium and soya groups. In liver, adipose, and heart tissues, Ahiflower raised EPA levels comparably to Echium oil, and significantly more than the control.

Implications for Inflammatory Status

The trial also monitored the impact of these dietary oils on omega-6 arachidonic acid (ARA), a biomarker associated with systemic inflammation when present in high circulating concentrations, highlighted Natures Crops International. As the study notes, one reason omega-3 fatty acids are consumed is to reduce inflammation to help prevent cardiovascular disease. Ahiflower oil lowered ARA levels across all studied tissues and blood components relative to soya oil. Furthermore, Ahiflower demonstrated a more pronounced reduction of ARA in liver than Echium oil.

Market Relevance for Product Formulators

For nutraceutical brand owners and manufacturers, these findings support the functional viability of plant-based omega-3 options, Natures Crops International explains, noting that the data indicates that mammals can synthesize necessary DHA from plant-based precursors without encountering the inhibition pathways sometimes observed when consuming preformed DHA.

Commenting on the study, Greg Cumberford, Science Lead at Natures Crops International stated, “This new animal study supports dietary Ahiflower oil for its heart health and exercise performance value, notably for raising EPA across all tissues studied including the heart, and more significantly in RBCs and plasma than Echium oil. It also shows how the body closely controls DHA accrual in heart and brain tissues thought to benefit most from higher omega-3 intakes. This is a different story, challenging the dominant view that plant-based omegas are ‘poorly’ converted to DHA. Rather it demonstrates the mammal body’s affinity for plant-based ALA+SDA sources which significantly raise EPA and maintain DHA levels across the whole body. When DHA is required to support brain and heart function, the body rapidly and efficiently makes it.”

The company also states that Ahiflower oil is increasingly being utilized in mass-market omega-3-6-9 formulations, including brands like Sam's Club Member's Mark, Garden of Life, MegaFood, Arbonne, and LifePlus. From a formulation perspective, it explains, manufacturers are adopting these botanical ingredients due to consumer preferences for neutral taste and aroma profiles over traditional flax, fish, or algal oils, alongside their versatile blending compatibility in ready-to-mix (RTM) bulk powders and stable emulsions.

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. Segre LV, Bisinotto MS, Castro IA. Eicosapentaenoic and Docosahexaenoic Acid Levels in Mouse Tissues After Intake of Echium and Ahiflower Oils Rich in Stearidonic and α-Linolenic Acids. Lipids. Published online February 13, 2026. doi:10.1002/lipd.70041
2. Natures Crops International. SDA-rich Ahiflower® oil raises blood DHA, maintains heart and brain DHA levels while boosting EPA more than Echium oil. Press release provided via email May 21, 2026. Accessed May 22, 2026.